New drug cocktail shows promise for rare sarcomas

NCT ID NCT03526679

Completed Disease control Sponsor: National Taiwan University Hospital Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tested a combination of two drugs, lenvatinib and eribulin, in 30 people with advanced soft tissue sarcomas (liposarcoma or leiomyosarcoma) that could not be removed by surgery or had spread. The goal was to see if the combo could shrink tumors or slow their growth. The trial is now complete, and results will help decide if this approach deserves further study.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: lenvatinib and eribulin
What this could lead to: If it works, this combination could offer a new treatment option for people with advanced soft tissue sarcomas that are hard to treat.
What could go wrong: This is a small, early-phase trial with only 30 participants, so results may not apply to everyone. The drugs can cause side effects like fatigue, nausea, and high blood pressure.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cancer leiomyosarcoma liposarcoma sarcoma soft tissue sarcoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADVANCED CANCER LEIOMYOSARCOMA LIPOSARCOMA SOFT TISSUE SARCOMA ADULT

Contacts and locations

Locations

National Taiwan University Hospital

Taipei, 100, Taiwan
Taipei Veterans General Hospital

Taipei, Taiwan, Taiwan

More trials for these conditions

Other studies related to the condition(s) this trial covers.